COPD_BERGEN_Fastq175

Resulting Illumina fastq files from 175 sputum samples collected as part of the Bergen COPD Cohort Study (BCCS) and its adjunct Bergen COPD Exacerbation Study (BCES)

Serum levels of 25(OH)D in ng/mL, mean±sd, for different potential explanatory variables by subject category.

*<p>BMI: body mass index.</p>#<p>Exacerbations requiring either hospitalisation or treatment with oral antibiotics or oral steroids.</p>§<p>PaO₂: arterial oxygen tension.</p>**<p>Associations were tested with t-test and ANOVA.</p

Baseline characteristics of the study sample, presented as mean±sd for continuous and percentage for categorical variables.

§<p>BMI: body mass index.</p>*<p>FEV₁: Forced expiratory volume in 1 s.</p>##<p>Season was defined as winter (December-March), spring (April-May), summer (June-September), and autumn (October–November).</p>#<p>Exacerbations requiring either hospitalisation or treatment with oral antibiotics or oral steroids.</p>§§<p>PaO₂: arterial oxygen tension.</p>**<p>Associations were tested with t-test and Chi-square.</p

Correlation analysis of continuous variables associated with baseline concentrations of serum 25(OH)D.

#<p>BMI: Body mass index.</p>§<p>PaO₂: Arterial oxygen tension.</p

Coefficients from multiple linear regression and logistic regression models, showing the relationship between baseline predictors and serum levels of 25(OH)D in COPD patients.

*<p>For both the linear and logistic regression models a backward stepwise procedure was used with the following variables included at start: Age, sex, GOLD status, hypoxemia (resting PaO₂<8), dyspnea (grade III), inhaled steroids, ICS (yes or no), *body mass index (BMI), comorbidity (Charlsons score <2 or ≥2), total white blood count, treatment for osteoporosis (yes or no), depression (CES-D score≥16) and exacerbation frequency (≥2 last year; yes or no).</p>#<p>Season was defined as winter (December–March), spring (April–May), summer (June–September), and autumn (October–November).</p

Forced expiratory volume in 1 s (FEV₁) plotted as a function of serum 25(OH)D levels for COPD patients and controls.

<p>The Pearson coefficient (r) is calculated and given in the graph.</p

Multivariate model of the annual incidence rate ratio (IRR) of moderate or severe COPD exacerbations, estimated by a random effects negative binomial model.

<p>*IRR per 1 SD increase of marker value.</p><p>Multivariate model of the annual incidence rate ratio (IRR) of moderate or severe COPD exacerbations, estimated by a random effects negative binomial model.</p

Characteristics of COPD patients according to exacerbation frequency during follow-up.

<p>*χ-square for categorical variables, t-test for means and Kruskal Wallis test for medians</p><p>Characteristics of COPD patients according to exacerbation frequency during follow-up.</p

Multivariate model of copd-exacerbation duration more than three weeks, estimated by a generalized estimation equation logistic regression model.

<p>Multivariate model of copd-exacerbation duration more than three weeks, estimated by a generalized estimation equation logistic regression model.</p

Bivariate predictors of copd-exacerbation duration more than three weeks, estimated by a generalized estimation equation logistic regression model.

<p>*IRR per 1 SD increase of marker value.</p><p>Bivariate predictors of copd-exacerbation duration more than three weeks, estimated by a generalized estimation equation logistic regression model.</p